Arrowhead Pharmaceuticals, Inc.
ARWR
주식 순위
#2432
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena,... Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
주가
$58.77
시가총액
$8.30B
변동 (1일)
2.70%
변동 (1년)
52.78%
국가
US
거래 Arrowhead Pharmaceuticals, Inc. (ARWR)
카테고리
Healthcare
Arrowhead Pharmaceuticals, Inc. (ARWR)의 P/S 비율
October 2026 기준 P/S 비율 TTM: 12.28
Arrowhead Pharmaceuticals, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 12.28입니다. 2024년 말 기준 P/S 비율은 653.40였습니다.
Arrowhead Pharmaceuticals, Inc.의 P/S 비율 기록 (2000 ~ 2026)
매년 말 P/S 비율
| 연도 | P/S 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 12.28 | 120.87% |
| 2025 | 5.56 | -99.15% |
| 2024 | 653.40 | 5,355.07% |
| 2023 | 11.98 | -16.39% |
| 2022 | 14.33 | -69.41% |
| 2021 | 46.84 | -4.98% |
| 2020 | 49.29 | 214.56% |
| 2019 | 15.67 | -84.26% |
| 2018 | 99.53 | 886.97% |
| 2017 | 10.08 | -99.64% |
| 2016 | 2.83K | 227.34% |
| 2015 | 864.88 | -78.15% |
| 2014 | 3.96K | 742.99% |
| 2013 | 469.60 | 141.37% |
| 2012 | 194.56 | 105.99% |
| 2011 | 94.45 | -13.31% |
| 2010 | 108.95 | 1,263.14% |
| 2009 | 7.99 | -74.44% |
| 2008 | 31.28 | -78.93% |
| 2007 | 148.45 | -44.56% |
| 2006 | 267.77 | 108.36% |
| 2005 | 128.52 | -65.53% |
| 2004 | 372.80 | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | 10.88 | -12.88% |
| 2001 | 12.48 | -45.86% |
| 2000 | 23.06 | 0.00% |
유사 기업 또는 경쟁사의 P/S 비율
| 회사 | P/S 비율 | P/S 비율 차이 | 국가 |
|---|---|---|---|
| 10.02 | -18.39% |
US
|
|
| 40.55 | 230.20% |
US
|
|
| 3.96 | -67.75% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -17.38% |
NL
|
